focus -WSS

focus

author：Wikipedia 2025-10-02 00:39:42 - browse：733

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Childhood vaccination ad campaign launches in the U.K.

hotspot

WSS

STAT Madness 2024: Meet the contenders

Redefining sustainability for the pharmaceutical industry

Ohio train derailment: Experts on toxic chemical risks

Laying a path for careers in science

Color Health wants to make cancer screenings convenient

Covid vaccine financial winners and losers, from Pfizer to Novavax

knowledge

focus

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Trump demands the U.S. pay no more for drugs than other countries … again

Decaf coffee targeted by food safety group under obscure FDA rule

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

At least 13 dead in Texas as scorching temps continue

Study says nonprofit hospitals fall short in charity care spending

State Dept. review finds Biden bears some blame for Afghanistan failures

Children’s Hospital revives plan for pedestrian bridge

focus

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

STAT Madness 2024: Meet the contenders

'Vaccine

5 ways to address the shortage of health care workers

Wikipedia

hotspot

entertainment

knowledge